









Markets
/
Stocks
/
nasdaq-sbfm
/

Sunshine Biopharma Inc

SBFM

1.200USD

+0.050+4.35%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

5.47MMarket Cap

0.23P/E TTM



Sunshine Biopharma Inc

1.200

+0.050+4.35%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sunshine Biopharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

Sunshine Biopharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sunshine Biopharma Inc's Score

Industry at a Glance

Industry Ranking

110 / 159

Overall Ranking

321 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Sunshine Biopharma Inc Highlights

StrengthsRisks

Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 702.52% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 34.87M.

Overvalued

The company’s latest PE is 0.23, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 370.31K shares, decreasing 26.68% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 55.70K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+421.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Sunshine Biopharma Inc is 8.57, ranking 57 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 9.42M, representing a year-over-year increase of 11.64%, while its net profit experienced a year-over-year increase of 26.21%.

Score

Industry at a Glance

Previous score

8.57

Change



Financials

8.72

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.91

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.43

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Sunshine Biopharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Sunshine Biopharma Inc is 8.14, ranking 30 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 0.23, which is 35.86% below the recent high of 0.31 and 756.56% above the recent low of -1.48.

Score

Industry at a Glance

Previous score

8.14

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 110/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Sunshine Biopharma Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+421.74%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Sunshine Biopharma Inc

SBFM

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Sunshine Biopharma Inc is 1.05, ranking 159 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.35 and the support level at 1.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.06

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Sell

RSI(14)

41.565

Neutral

STOCH(KDJ)(9,3,3)

17.821

Oversold

ATR(14)

0.068

High Vlolatility

CCI(14)

-130.649

Sell

Williams %R

75.000

Sell

TRIX(12,20)

-0.343

Sell

StochRSI(14)

95.414

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.204

Sell

MA10

1.229

Sell

MA20

1.237

Sell

MA50

1.318

Sell

MA100

1.490

Sell

MA200

1.477

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Sunshine Biopharma Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 7.55%, representing a quarter-over-quarter increase of 188.98%. The largest institutional shareholder is James Simons, holding a total of 55.70K shares, representing 1.14% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

L1 Global Manager Pty Limited

142.24K

+5281.91%

Citadel Advisors LLC

78.09K

+23.11%

Renaissance Technologies LLC

Star Investors

55.70K

+2.97%

DRW Securities, LLC

44.98K

Two Sigma Investments, LP

38.58K

SBI Securities Co., Ltd.

4.85K

-27.55%

Morgan Stanley Smith Barney LLC

3.83K

UBS Financial Services, Inc.

206.00

Chamoun (Malek)

1.85K

Osaic Holdings, Inc.

152.00

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sunshine Biopharma Inc is 2.32, ranking 130 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.